Quest Diagnostics (Quest Diagnostics) Retained Earnings

: $8,825 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Quest Diagnostics's retained earnings for the quarter that ended in Dec. 2023 was $8,825 Mil.

Quest Diagnostics's quarterly retained earnings increased from Jun. 2023 ($8,566 Mil) to Sep. 2023 ($8,711 Mil) and increased from Sep. 2023 ($8,711 Mil) to Dec. 2023 ($8,825 Mil).

Quest Diagnostics's annual retained earnings increased from Dec. 2021 ($7,649 Mil) to Dec. 2022 ($8,290 Mil) and increased from Dec. 2022 ($8,290 Mil) to Dec. 2023 ($8,825 Mil).

Quest Diagnostics Retained Earnings Historical Data

The historical data trend for Quest Diagnostics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest Diagnostics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

8,174.00

9,303.00

7,649.00

8,290.00

8,825.00

Quest Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															8,290.00	8,412.00	8,566.00	8,711.00	8,825.00

Quest Diagnostics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Quest Diagnostics (NYSE:DGX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Quest Diagnostics (Quest Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Quest Diagnostics Inc (NYSE:DGX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

QDI:Germany

Address

500 Plaza Drive, Secaucus, NJ, USA, 07094

Website

https://www.questdiagnostics.com

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Executives

Luis Diaz	director	C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02138
Michael E Prevoznik	officer: Corp VP, Legal & Compliance	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Catherine T. Doherty	officer: SVP, Physician Services Bus.	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Timothy M Ring	director	C/O C.R BARD INC, 730 CENTRAL AVE, MURRAY HILL NJ 07974
Mark E Delaney	officer: SVP & Chief Commercial Officer	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Mark A Gardner	officer: SVP of Molecular Gen & Oncol	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Patrick Plewman	officer: SVP for Diagnostic Services	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Karthik Kuppusamy	officer: SVP, Clinical Solutions	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS NJ 07094
Michael J Deppe	officer: VP, Corp. Controller & CAO	500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS, SECAUCUS NJ 07094
Samer Abdul Samad	officer: Executive Vice President & CFO	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Stephen H Rusckowski	director, officer: President and CEO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Tracey Doi	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Gail R Wilensky	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Mark Guinan	officer: Senior Vice President & CFO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Daniel Stanzione	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094